SAN DIEGO, Nov. 14, 2012 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that results from the largest study of its kind show that stent procedures guided by intravascular ultrasound (IVUS) resulted in better patient outcomes and fewer complications at 30 days and 12 months compared to procedures without IVUS, and were safe.
On 13 November, Biotronik launched its 3Flow Aspiration Catheter. According to a company release, this catheter is specifically designed to facilitate quick and accurate thrombus aspiration.
BUELACH, Switzerland, November 13, 2012 – BIOTRONIK, a leading manufacturer of innovative medical technology, today launched its 3Flow Aspiration Catheter. The catheter is specifically designed to facilitate quick and accurate thrombus aspiration, complementing BIOTRONIK’s already broad Coronary Vascular Intervention (CVI) portfolio.
NEW YORK (AP) — A Jefferies & Co. analyst said Tuesday that a study appears to show new problems with the wires in St. Jude Medical Inc. s implantable heart devices.
Medtronic Inc. lost a second round against rival med-tech company Edwards Lifesciences when an appeals court upheld a jury s decision that said Medtronic infringed on an Edwards patent.
At the 2012 Transcatheter Cardiovascular Therapeutics (TCT; 22–26 October, Miami, USA) meeting, reporting on the results of an economic analysis of the FAME II study, William Fearon, Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, USA, said that fractional flow reserve (FFR) guided percutaneous coronary intervention (PCI) was cost-effective, compared with medical management, in patients with stable coronary disease (CAD).
InspireMD has announced that the randomised 432-patient MASTER trial of its embolic protective MGuard Embolic Protection Coronary Stent (EPS) has been published in the 6 November print edition of the Journal of American College of Cardiology.
The results from a five-year study of diabetics with diseased arteries has found that patients who have bypass surgery fare significantly better than those who undergo clearing procedures supported by implanted drug-coated stents.
(Reuters) - St Jude Medical Inc said on Monday its procedure that deadens nerves near the kidneys helped lower blood pressure in a small study of patients whose hypertension could not be controlled with drugs.
People with diabetes mellitus who undergo heart bypass surgery for multiple blocked arteries have a significantly better five-year survival rate than diabetic patients who undergo angioplasty with drug-eluting stents (DES), according to a study published in the November 2012 issue of The Annals of Thoracic Surgery.
The results from a five-year study of diabetics with diseased arteries has found that patients who have bypass surgery fare significantly better than those who undergo clearing procedures supported by implanted drug-coated stents.
Boston Scientific has received CE mark approval for the Synergy Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.
SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Fish & Richardson scored a major victory for San Diego based Volcano Corporation in a patent trial regarding medical device technology used to diagnose heart problems. After less than 90 minutes of deliberation, a federal district court jury in Delaware found that Volcano did not infringe two patents asserted by St. Jude Medical Inc. and that another two St. Jude patents were invalid. A fifth St. Jude patent was declared not infringed by the court on the eve of trial. The lawsuit, filed in 2010 by St. Jude, sought to shut down Volcano s rapidly growing cardiac Functional Management business. The verdict was delivered on October 19, 2012 and was initially subject to an agreement by the parties not to issue press releases.
WAYNE, N.J., Oct. 29, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS® 7.5Fr. 40cc intra-aortic balloon (IAB) catheter.
Results of the XIMA trial presented at TCT 2012
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos